Transformational
Disease-Modifying
Advances in the Treatment
of Keratoconus & Myopia
Disease-Modifying
Advances in the Treatment
of Keratoconus & Myopia
About iVeena
iVeena Delivery Systems, Inc. is a privately held, clinical stage ophthalmology company developing non-surgical, non-invasive, pharmacologic innovations. These novel disease modifying interventions address significant unmet needs in the treatment of corneal disease and myopic conditions.
What We Do
Lead programs comprise of novel proprietary eye drops; IVMED-80 (granted ODD) for keratoconus, and IVMED-85 for myopia.
News
-
August 24, 2022iVeena enters into a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic ..
-
November 10, 2021SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems (iVeena), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, announces successful ..
-
April 27, 2021April 27, 2021 – Salt Lake City, UT – iVeena, a clinical stage ophthalmology company addressing unmet medical need in the pharmacologic treatment of corneal dystrophies and myopic conditions, ..